Liraglutide clinical trials antidiabetic drugs

victoza - liraglutide

Diabetes type 2

All type of patients:  44 trials  - LEADER - Kaku 0.6mg - Kaku 0.9mg - Pratley (1.8 vs 1.2) - Pratley 1.2mg - Pratley 1.8mg - Seino - LEAD 1 (1.8 vs 1.2) - LEAD 2 (1.8 vs 1.2) - LEAD 4 (1.8 vs 1.2) - LEAD-1 SU (1.2 mg vs placebo) - LEAD-1 SU (1.2 vs rosiglitazone) - LEAD-1 SU (1.8 mg vs placebo) - LEAD-1 SU (1.8 vs rosiglitazone) - LEAD-2 (Nauck) (1.2 mg vs glimepiride) - LEAD-2 (Nauck) (1.2mg vs placebo) - LEAD-2 (Nauck) (1.8 mg vs glimepiride) - LEAD-2 (Nauck) (1.8mg vs placebo) - LEAD-3 mono 1.2mg (Garber) - LEAD-3 mono 1.8mg (Garber) - LEAD-4 (1.2mg) - LEAD-4 (1.8mg) - LEAD-5 (vs Glargine) - LEAD-5 (vs placebo) - LEAD-6 - Seino - NN2211-1571 (Vilsbøll) - Feinglos - Harder - Madsbad (vs Glimepiride) - Madsbad (vs placebo) - EAGLE - LIBRA - MK-0431-403 - NCT00978393 - NCT01234649 - NN2211-1701 - NN2211-1796 - NN2211-1799 - NN2211-1800 - NN2211-3619 - NN8022-1922 - NN8022-1923 - NN2211-1333

Patients inadequately controlled on MET+SU therapy :  3 trials  - LEAD-5 (vs Glargine) - LEAD-5 (vs placebo) - LEAD-6

Patients inadequately controlled on metformin:  6 trials  - Pratley 1.2mg - Pratley 1.8mg - LEAD-2 (Nauck) (1.8 mg vs glimepiride) - LEAD-2 (Nauck) (1.8mg vs placebo) - MK-0431-403 - NN2211-1799

Patients inadequately controlled on monotherapy :  13 trials  - Pratley 1.2mg - Pratley 1.8mg - Seino - LEAD-1 SU (1.2 mg vs placebo) - LEAD-1 SU (1.8 mg vs placebo) - LEAD-1 SU (1.8 vs rosiglitazone) - LEAD-2 (Nauck) (1.8 mg vs glimepiride) - LEAD-2 (Nauck) (1.8mg vs placebo) - LEAD-5 (vs Glargine) - LEAD-5 (vs placebo) - MK-0431-403 - NN2211-1701 - NN2211-1799

Patients inadequately controlled with insulin:  1 trials  - EAGLE

Patients with insufficient glycaemic control with bitherapy:  3 trials  - LEAD-4 (1.2mg) - LEAD-4 (1.8mg) - LEAD-6

Obesity and overweight

1 trials  - Astrup (NN8022-1807 )